Oncopeptides AB (publ) (ONPPF) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Oncopeptides AB (publ) (ONPPF) Healthcare & Pipeline Overview

Oncopeptides AB (publ) is a Swedish biotech firm specializing in cancer therapeutics, particularly melflufen for relapsed refractory multiple myeloma. With a focus on the US and European markets, the company navigates a competitive landscape with a negative P/E ratio of -1.77 and a volatile beta of -0.55.

What Is the Investment Thesis for ONPPF?

Oncopeptides presents a high-risk, high-reward investment opportunity within the biotechnology sector. The core of the investment thesis revolves around the potential success and market adoption of melflufen in the treatment of relapsed refractory multiple myeloma. The company's current market capitalization is approximately $60 million. Key catalysts include regulatory approvals in major markets and successful commercialization strategies. However, the company's negative P/E ratio of -1.77 and a negative profit margin of -350.4% highlight significant financial challenges. Investors should closely monitor clinical trial outcomes, regulatory decisions, and the company's ability to secure funding and partnerships to support its operations and commercialization efforts.

Based on FMP financials and quantitative analysis

ONPPF Key Highlights

Melflufen is Oncopeptides' lead product candidate, targeting relapsed refractory multiple myeloma.

• The company has a gross margin of 96.6%, indicating strong potential profitability if sales volumes increase.
• Oncopeptides operates in the United States, Europe, and internationally, seeking to expand its market reach.
• The company's market capitalization is $0.06 billion, reflecting its current valuation in the biotech market.
• The company has a negative P/E ratio of -1.77 and a profit margin of -350.4%, indicating financial challenges.

Who Are ONPPF's Competitors?

ONPPF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ONPPF's Key Strengths?

Novel peptide-drug conjugate technology.

• Targeted therapy for relapsed refractory multiple myeloma.
• High gross margin of 96.6%.
• Experienced management team.

What Are ONPPF's Weaknesses?

Negative P/E ratio and profit margin.

• Reliance on a single lead product candidate.
• Limited commercial infrastructure.
• High cash burn rate.

What Could Drive ONPPF Stock Higher?

Potential regulatory approvals for melflufen in key markets.

• Clinical trial results for melflufen in expanded indications.
• Strategic partnerships with pharmaceutical companies.
• Expansion of commercial infrastructure and sales force.
• Advancement of pipeline candidates through clinical development.

What Are the Key Risks for ONPPF?

Financial-distress signal — its Altman Z-Score of -2.59 sits in the distress zone (elevated bankruptcy risk).

• Regulatory setbacks or rejection of melflufen.
• Competition from established pharmaceutical companies.
• Clinical trial failures or unexpected adverse events.
• Patent expiration and loss of exclusivity.
• Financial challenges and need for additional funding.

What Are the Growth Opportunities for ONPPF?

• Expansion of Melflufen's Indications: Oncopeptides has the opportunity to expand the use of melflufen beyond relapsed refractory multiple myeloma to other hematological malignancies or solid tumors. This would require additional clinical trials and regulatory approvals, but could significantly increase the potential market for the drug. The global oncology market is projected to reach $286.6 billion by 2030, providing a substantial opportunity for Oncopeptides to capture a larger share with expanded indications. Timeline: 3-5 years.
• Strategic Partnerships and Collaborations: Oncopeptides can pursue strategic partnerships with larger pharmaceutical companies to co-develop and commercialize its products. This would provide access to additional funding, expertise, and distribution networks, accelerating the commercialization of melflufen and other pipeline candidates. The pharmaceutical industry is increasingly reliant on collaborations to drive innovation, making this a viable growth strategy. Timeline: Ongoing.
• Geographic Expansion: Oncopeptides can expand its geographic presence beyond the United States and Europe to emerging markets in Asia and Latin America. These markets offer significant growth potential due to increasing healthcare spending and a growing prevalence of cancer. However, this would require navigating complex regulatory environments and establishing local partnerships. Timeline: 2-4 years.
• Advancement of Pipeline Candidates: Oncopeptides can invest in the development of its earlier-stage pipeline candidates to create a more diversified product portfolio. This would reduce the company's reliance on melflufen and provide additional growth opportunities in the future. The biotechnology industry is characterized by a constant need for innovation, making pipeline development a critical growth driver. Timeline: 5+ years.
• Personalized Medicine Approaches: Oncopeptides can explore personalized medicine approaches to identify patients who are most likely to respond to melflufen. This would involve using biomarkers and genetic testing to tailor treatment decisions, improving efficacy and reducing the risk of adverse events. The personalized medicine market is growing rapidly, driven by advancements in genomics and diagnostics. Timeline: 3-5 years.

What Are ONPPF's Competitive Advantages?

• Patented drug candidates provide exclusivity and protection from competition.
• Specialized expertise in peptide-drug conjugate technology.
• Clinical data demonstrating the efficacy and safety of its therapies.
• Established relationships with key opinion leaders in the oncology field.

What Does ONPPF Do?

Oncopeptides AB (publ) is a Swedish biotechnology company founded in 2000 and headquartered in Stockholm. The company is dedicated to developing innovative pharmaceutical drugs for the treatment of cancer, with a primary focus on addressing unmet needs in hematological malignancies. Their lead product candidate, melflufen, is a peptide-drug conjugate designed to selectively deliver cytotoxic agents to cancer cells, specifically targeting relapsed refractory multiple myeloma (RRMM) in adult patients. Melflufen is designed to improve the treatment outcomes for patients who have limited therapeutic options. Oncopeptides operates in the United States, Europe, and other international markets, seeking regulatory approvals and commercial partnerships to bring its therapies to a global patient population. The company's research and development efforts are centered on advancing its pipeline of targeted cancer treatments, aiming to provide more effective and less toxic alternatives to conventional chemotherapy. Oncopeptides faces competition from established pharmaceutical companies and other biotech firms developing therapies for multiple myeloma, requiring a strategic approach to market access and product differentiation. The company employs 80 individuals.

What Products and Services Does ONPPF Offer?

• Develops pharmaceutical drugs for cancer treatment.
• Focuses on targeted therapies for hematological malignancies.
• Creates peptide-drug conjugates to selectively deliver cytotoxic agents to cancer cells.
• Aims to improve treatment outcomes for patients with limited therapeutic options.
• Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
• Seeks regulatory approvals in the United States, Europe, and other international markets.
• Commercializes its products through partnerships and direct sales.

How Does ONPPF Make Money?

• Develops and patents novel cancer therapies.
• Conducts clinical trials to demonstrate safety and efficacy.
• Seeks regulatory approval from agencies like the FDA and EMA.
• Commercializes approved drugs through direct sales or partnerships.

What Industry Does ONPPF Operate In?

Oncopeptides operates within the competitive biotechnology industry, specifically targeting the oncology market. The industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition from both established pharmaceutical giants and emerging biotech firms. The market for multiple myeloma treatments is substantial and growing, driven by an aging population and advancements in diagnostic techniques. Oncopeptides faces competition from companies like ACOGF, BSTG, DMTTF, HRPMF, and KDEVF, which are developing or marketing therapies for similar indications. The success of Oncopeptides depends on its ability to differentiate its products, secure regulatory approvals, and establish a strong commercial presence.

Who Are ONPPF's Key Customers?

• Adult patients with relapsed refractory multiple myeloma.
• Oncologists and hematologists who treat cancer patients.
• Hospitals and cancer centers that administer cancer therapies.
• Pharmacies that dispense prescription drugs.

Oncopeptides AB (publ) Financial Trajectory

Oncopeptides AB (publ) (ONPPF) reported $13.3M in revenue for Q1 2025, reflecting 33.8% growth compared to the prior quarter. The company recorded a net loss of $60.7M, with diluted EPS of $-0.28. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap Healthcare company. Across the four most recent quarters, ONPPF averaged $-0.39 in diluted EPS.

Company Profile

Oncopeptides AB (publ) operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Stockholm, SE. The company is led by CEO Sofia Heigis. ONPPF has traded publicly since 2020.

How Oncopeptides AB (publ) Is Valued

Oncopeptides AB (publ) carries a market capitalization of $56.0M, placing it in the micro-cap category. Relative to its peer group, ONPPF's quantitative score of 53/100 is roughly in line with the peer average of 48/100.

Key Financial Metrics

Return on assets is -81.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -48.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.55 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -50.1%, the inverse of the P/E and a quick read on earnings relative to price.

Oncopeptides AB (publ)'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -2.59 places it in the distress zone, a signal of elevated financial risk.

Oncopeptides AB (publ) has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 9.3% below estimates on average.

Wall Street analysts project Oncopeptides AB (publ) revenue of about $183.4M for fiscal 2026, with EPS near $-0.18. The estimate reflects 3 contributing analysts.

ONPPF Financials

ONPPF Latest News

No recent news available for ONPPF.

ONPPF Analyst Consensus

ONPPF MoonshotScore

What Investors Ask About Oncopeptides AB (publ) (ONPPF) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources